Britain Approves Emergency Use of Pfizer COVID-19 Vaccine
WEDNESDAY, Dec. 2, 2020 -- Britain became the first Western country to allow emergency use of a COVID-19 vaccine on Wednesday after approving the Pfizer vaccine candidate in the race to inoculate millions of people around the globe.
Though Britain has an early jump on distribution of the Pfizer vaccine, it will have no effect on the distribution of the hundreds of millions of doses that other wealthy countries like the United States have bought in prepaid contracts, The New York Times reported.
But there are daunting obstacles to the vaccine's delivery to the masses. The Pfizer vaccine, developed with the German firm BioNTech, must be kept at the very cold temperature of –94 degrees Fahrenheit until shortly before shots are given. However, Pfizer said in a statement released Wednesday that it has developed special shipping containers that use dry ice to keep the vaccine cold. GPS sensors will allow the company to track each shipment and ensure it stays cold, the company added.
Still, the temperature requirement could dictate who will be vaccinated first in Britain: While nursing home residents were supposed to be the top priority under an advisory committee's plans, efforts to limit transportation of the vaccine may mean that National Health Service staff will receive the shots first, The Times reported. The British government said Wednesday that 800,000 doses would be available by next week for health care workers to begin administering.
In the United States, an advisory panel on Tuesday approved a vaccine distribution plan that recommends health care workers and nursing home residents and staff be the first to receive any approved COVID-19 vaccine. The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. A U.S. Food and Drug Administration advisory panel is set to meet on Dec. 10 to decide whether the agency should grant emergency use authorization to the Pfizer vaccine, The Times reported.
© 2021 HealthDay. All rights reserved.
Posted: December 2020
Further Support and Information on COVID-19
Read this next
FRIDAY, Jan. 22, 2021 -- Treatment with bamlanivimab and etesevimab, but not monotherapy with bamlanivimab, is associated with a reduction in severe acute respiratory syndrome...
FRIDAY, Jan. 22, 2021 -- There was a decrease in the total number of pediatric emergency department visits in 2020, but the proportion of trauma-related visits increased,...
THURSDAY, Jan. 21, 2021 -- Overall, 2.3 percent of kindergarteners were not up to date with measles, mumps, and rubella (MMR) vaccination and did not have an exemption in the 2019...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.